Citation Impact
Citing Papers
Increased Prevalence of Sleep-Disordered Breathing in Adults
2013 Standout
Topological control of cytokine receptor signaling induces differential effects in hematopoiesis
2019 StandoutScienceNobel
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Effective treatment of severe COVID-19 patients with tocilizumab
2020 Standout
Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
2012
The UK Biobank resource with deep phenotyping and genomic data
2018 StandoutNature
Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
2016
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
2014
Autoimmune Th17 Cells Induced Synovial Stromal and Innate Lymphoid Cell Secretion of the Cytokine GM-CSF to Initiate and Augment Autoimmune Arthritis
2018 StandoutNobel
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
2014
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
2020
Cytokines in inflammatory bowel disease
2014 Standout
N6-Methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO
2011 StandoutNobel
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Targeting JAK kinase in solid tumors: emerging opportunities and challenges
2015
Health benefits of physical activity: the evidence
2006 Standout
JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
2012
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
2014
Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
2014
Covalent docking of large libraries for the discovery of chemical probes
2014
NF-κB signaling in inflammation
2017 Standout
Myasthenia Gravis
2016 Standout
Targeting Interleukin-6 Signaling in Clinic
2019
Rheumatoid arthritis
2018 Standout
Rheumatoid arthritis
2016 Standout
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
2015
Familial chilblain lupus due to a gain-of-function mutation in STING
2016
Human Genetics Shape the Gut Microbiome
2014 Standout
JAKs and STATs in Immunity, Immunodeficiency, and Cancer
2013
Association among serum lipid and lipoprotein concentrations and physical activity, physical fitness, and body composition in young children
1993
Post-transcriptional gene regulation by mRNA modifications
2016 Standout
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
2013
The problem of choice: current biologic agents and future prospects in RA
2013
Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment
2012
The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations
2015
Observations on Physical Activity in Physical Locations: Ager Gender, Ethnicity, and Month Effects
1993
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
2016
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
2020
Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition
2017
IL-6 as a keystone cytokine in health and disease
2015 Standout
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
2012
LD Score regression distinguishes confounding from polygenicity in genome-wide association studies
2015 Standout
Dynamic RNA Modifications in Gene Expression Regulation
2017 Standout
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
2013 Standout
Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts
2015
Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis
2012
Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
2010
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease
2016
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Crohn's disease
2016 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis
2017
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Deep learning in histopathology: the path to the clinic
2021 Standout
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
2020
Loss-of-Function Mutation in the Dioxygenase-Encoding FTO Gene Causes Severe Growth Retardation and Multiple Malformations
2009 StandoutNobel
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: Implications for future therapeutic approaches
2010
Inflammation and Bone Destruction in Arthritis: Synergistic Activity of Immune and Mesenchymal Cells in Joints
2012
The emerging safety profile of JAK inhibitors in rheumatic disease
2017
Current jakinibs for the treatment of rheumatoid arthritis: a systematic review
2021
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
2011
The microbiome and rheumatoid arthritis
2011
Ulcerative colitis
2016 Standout
‘Small Changes' to Diet and Physical Activity Behaviors for Weight Management
2013 Standout
Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib
2020
Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases
2018 Standout
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
2017
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
2020
Intracellular signal pathways: Potential for therapies
2009
Rheumatoid arthritis
2010 Standout
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
2018
Functional Specialization of Interleukin-17 Family Members
2011 Standout
Baricitinib in Patients with Refractory Rheumatoid Arthritis
2016
T cell migration in rheumatoid arthritis
2015
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
2018
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
2017
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
2016
Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example
2014
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
2014 Standout
Biological Therapies of Immunologic Diseases
2017
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
2015
Validating therapeutic targets through human genetics
2013
Genetics of Food Intake Self-Regulation in Childhood: Literature Review and Research Opportunities
2013 Standout
Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial
2015
Obesity and the Metabolic Syndrome in Children and Adolescents
2004 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Dispensable roles of Gsdmd and Ripk3 in sustaining IL-1β production and chronic inflammation in Th17-mediated autoimmune arthritis
2021 StandoutNobel
Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy
2010
Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis
2009 Standout
The human microbiome: at the interface of health and disease
2012 Standout
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
2017
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
Review article: novel oral‐targeted therapies in inflammatory bowel disease
2018
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
2013
Therapeutic Efficacy of Suppressing the JAK/STAT Pathway in Multiple Models of Experimental Autoimmune Encephalomyelitis
2013
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
2017
JAK2 activation by growth hormone and other cytokines
2015
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis
2021
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
2016
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Coordinative Alignment in the Pores of MOFs for the Structural Determination of N-, S-, and P-Containing Organic Compounds Including Complex Chiral Molecules
2019 StandoutNobel
Trends in Obesity Among Adults in the United States, 2005 to 2014
2016 Standout
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
2019
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
2015
Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood
2016
Clinically Important Changes in Short Form 36 Health Survey Scales for Use in Rheumatoid Arthritis Clinical Trials: The Impact of Low Responsiveness
2014
Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
2019
Targeting the JAK/STAT pathway in solid tumors
2020
Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
2020
Visceral fat in prepubertal children: Influence of obesity, anthropometry, ethnicity, gender, diet, and growth
1999
Cytokine Storm
2020 Standout
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
2018
Future perspectives in target-specific immunotherapies of myasthenia gravis
2015
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
2015
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
2016
Control of foreign Ag‐specific Ab responses by Treg and Tfr
2020 StandoutNobel
A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis
2020
Selective JAK inhibitors in development for rheumatoid arthritis
2014
TYK 2 inhibitors for the treatment of dermatologic conditions: the evolution of JAK inhibitors
2021
Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease
2014 StandoutScienceNobel
A Randomized, Double‐Blind, Placebo‐Controlled, Twelve‐Week, Dose‐Ranging Study of Decernotinib, an Oral Selective JAK‐3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
2014
Cannabinoids for Medical Use
2015 Standout
Accuracy of maternal dietary recall for preschool children
1991
Automated deep-learning system for Gleason grading of prostate cancer using biopsies: a diagnostic study
2020
Therapeutic Effects of STAT3 Inhibition on Experimental Murine Dry Eye
2019
VX‐509 (Decernotinib), an Oral Selective JAK‐3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
2015
Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
2020
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
2011
Baricitinib for the treatment of rheumatoid arthritis
2016
Works of David Gruben being referenced
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
2015
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis
2016
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
2009
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo
2009
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
2012
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
2013
Phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease‐modifying antirheumatic drugs
2011
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
2014
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
2016
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
2013
A phase IIb dose‐ranging study of the oral JAK inhibitor tofacitinib (CP‐690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
2011
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
2014
Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
2012
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
2016
Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial
2016
Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Trial
2014
Oral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy
2000
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study
2019
Effect of CP‐690,550, an Orally Active Janus Kinase Inhibitor, on Renal Function in Healthy Adult Volunteers
2009
Ethnic differences in anthropometric characteristics of young children and their parents.
1989
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
2016
Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
2013
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria
2016
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies
2016